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https://doi.org/10.1016/j.cmet.2020.11.003SUMMARYMitochondria constantly adapt to the metabolic needs of a cell. This mitochondrial plasticity is critical to
T cells, which modulate metabolism depending on antigen-driven signals and environment. We show here
that de novo synthesis of the mitochondrial membrane-specific lipid cardiolipin maintains CD8+ T cell func-
tion. T cells deficient for the cardiolipin-synthesizing enzyme PTPMT1 had reduced cardiolipin and re-
sponded poorly to antigen because basal cardiolipin levels were required for activation. However, neither
de novo cardiolipin synthesis, nor its Tafazzin-dependent remodeling, was needed for T cell activation. In
contrast, PTPMT1-dependent cardiolipin synthesis was vital when mitochondrial fitness was required,
most notably during memory T cell differentiation or nutrient stress. We also found CD8+ T cell defects in
a small cohort of patients with Barth syndrome, where TAFAZZIN is mutated, and in a Tafazzin-deficient
mouse model. Thus, the dynamic regulation of a single mitochondrial lipid is crucial for CD8+ T cell immunity.INTRODUCTION
Upon activation, CD8+ T cells shift from a quiescent to a highly
active metabolic state where both glycolysis and OXPHOS in-
crease (Bailis et al., 2019; Buck et al., 2017; Chang et al.,
2013; Geltink et al., 2018; Klein Geltink et al., 2017; Sena et al.,
2013). During this phase, mitochondria generate signals, such
as reactive oxygen species (ROS) or metabolites, required to
drive T cell differentiation (Bailis et al., 2019; Sena et al., 2013).
Although effector T (TE) cells increase aerobic glycolysis during
in vitro culture, they display greater rates of oxidative phosphor-
ylation (OXPHOS) in vivo (Ma et al., 2019). When the infection or
cancer has been eradicated, the majority of TE cells die, leaving
behind a small number of long-lived memory T (TM) cells that
confer long-term immune protection. TM cells engage catabolic
pathways like fatty acid oxidation (FAO) to fuel mitochondrial
respiration (Pearce et al., 2009; van der Windt et al., 2012). Over-
all, cellular metabolic changes supported bymitochondria are in-
tegral to a functional T cell response.
Mitochondria continuously undergo fusion and fission (Chan,
2020; Pernas and Scorrano, 2016), and Optic atrophy 1
(OPA1), a protein critical for mitochondrial shape and meta-
bolism (Cipolat et al., 2004; Cogliati et al., 2013; Frezza et al.,
2006), is required to generate TM cells (Buck et al., 2016). Mito-Cell Metabolism 32, 981–995, Dece
This is an open access article under the CC BY-Nchondria also differ at the sub-organellar level, where different
properties and lipid compositions exist between the inner
(IMM) and outer mitochondrial membrane (OMM) (Frey andMan-
nella, 2000). The IMM is organized in discrete invaginations
called cristae, where electron transport chain (ETC) complexes
are located (Mannella et al., 2001; Wolf et al., 2019). Cardiolipin
(CL) is exclusively synthesized and localized in the IMM and ac-
counts for 15%–20% of the total phospholipid mass (Dudek,
2017). CL is a four-acyl chain lipid with a small negative glycerol
polar head responsible for the negative curvature of the cristae.
Here, CL binds to ETC complexes, making respiration more effi-
cient and reducing ROS (Paradies et al., 2014), and also modu-
lates substrate carrier activity and protein import (Paradies et al.,
2019). When mislocalized to the OMM, CL recruits caspases,
promoting apoptosis or triggering an inflammatory response
(Gonzalvez et al., 2008; Iyer et al., 2013). In addition to its role
in heart andmuscle (Dudek et al., 2019), CL synthesis is essential
for systemic energy homeostasis to prevent insulin resistance
(Sustarsic et al., 2018).
CL composition varies greatly in both acyl chain length and
saturation, with the tetra-linoleic form (CL 72:8) being the most
abundant species (Minkler and Hoppel, 2010). CL localization
at the site of OXPHOSmakes it susceptible to oxidation by cyto-
chrome c (Kagan et al., 2005). When oxidation occurs,mber 1, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 981
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. De Novo Cardiolipin Synthesis Is a Hallmark of CD8+ T Cells with a High-Reserve Respiratory Capacity
(A) OCR of mouse WT CD8+ T cells activated with aCD3 only or aCD3/aCD28 and differentiated in IL-15 TM cells for 6 days. OCR analysis at baseline and after
exposure to aCD3/aCD28 coated beads, Oligomycin (Oligo), FCCP, and Rotenone/Antimycin (Rot/Ant).
(B) Lipids extracted from cells activated and differentiated as in (A). Data show Log2FC and p value calculated with ANOVA test.
(C) Total CL content in cells treated and analyzed as in (B).
(D) OCR of mouse WT CD8+ T cells activated with aCD3/aCD28 + IL-2 and cultured in complete medium until day 3, then cultured for 24 h in either complete
medium (10mM glucose) or glucose restricted medium (1mM glucose) for 24 h. Normalized OCR at baseline and after (Oligo) FCCP and Rot/Ant injections.
(legend continued on next page)
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OPEN ACCESSArticlephospholipases remove the altered acyl chain, generating an in-
termediate monolysocardiolipin (MLCL), which is then ‘‘remod-
eled’’ into mature CL by the enzyme TAFAZZIN (Hsu et al.,
2013; Schlame, 2013). Mutations in TAFAZZIN result in reduced
CL content in all cells (Schlame et al., 2003) and are responsible
for Barth syndrome, an X-linked recessive human disease char-
acterized by dilated cardiomyopathy, muscle weakness, and fa-
tigue (Barth et al., 1983; Bione et al., 1996; Clarke et al., 2013).
Neutropenia and susceptibility to infections have been reported
in 90% of Barth syndrome patients, but mechanistic analyses
into the impaired immunity is lacking (Steward et al., 2019).
Clinically relevant total lymphopenia has only been described
in one Barth syndrome patient, where it was a prelude to devel-
opment of non-Epstein Barr virus (EBV)-associated T cell non-
Hodgkin lymphoma following cardiac transplantation (Ronghe
et al., 2001).
Our previous work has shown how changes in mitochondrial
shape, cristae morphology, and function directly impact CD8+
T cell activation, differentiation, and functional TM cell develop-
ment (Buck et al., 2016; Klein Geltink et al., 2017; van der Windt
et al., 2012). The role of CL presence, de novo synthesis, or re-
modeling in the assumption of distinct metabolic programs
and mitochondrial function in T cells has not been investigated.
Given these collective observations, and the pivotal function of
CL in regulating OXPHOS and cristae structure, we set out to
investigate the role of CL in the CD8+ T cell response.
RESULTS
De Novo Synthesis of Cardiolipin Is a Hallmark of CD8+ T
Cells with High-Reserve Respiratory Capacity
We investigated how CL was modulated in CD8+ T cell culture
settings that invoked higher spare respiratory capacity (SRC), a
measure of a cell’s ability to make extra ATP from OXPHOS
upon increased energy demand (Nicholls, 2009). CD28 co-stim-(E) Lipids extracted from cells activated and differentiated as in (F). Data show L
(F) Total CL content in cells treated and analyzed as in (F).
(G) Immunoblot analysis of cells activated and differentiated as in (A).
(H) Immunoblot analysis of cells treated as in (D).
(I) MitoTracker Green staining in cells activated and differentiated as in (A).
(J) MitoTracker Green staining in cells activated and differentiated as in (D).
(K) SRC of CD8+ T cells activated as in (D) and cultured ± AD during 20 h of gluc
(L) Survival of CD8+ T cells activated as in (D) and cultured ± AD during 20 h of g
(M) OCR of mouseWT CD8+ T cells activated with aCD3/aCD28 + IL-2 and culture
or IL-15 (IL-15 TM).
(N) Lipids extracted from WT CD8+ T cells differentiated as in (M). Data show Lo
(O) Total CL content from IL-2 TE and IL-15 TM CD8
+ T cells cultured as in (M).
(P) Lipids extracted from TEM (CD44
hiCD62Llo) and TCM (CD44
hiCD62Lhi) cells isola
ANOVA test from 9 animals per group.
(Q) Total CL content from TEM and TCM cells isolated as in (P). Dots represent ind
(R) CD8+ T cells were activated with aCD3/aCD28 + IL-2 for 3 days and then differ
lipids were extracted and 13C-glucose derived carbons traced into CL 72:8.
(S) CD8+ T cells were activated with aCD3/aCD28 + IL-2 for 3 days and then differe
acid ± CL synthesis inhibitor (AD). 13C-glucose and 13C-linoleic acid derived car
(T) CD8+ T cells were differentiated as in (S). Also shown is the percentage of is
traced into CL 72:8.
Data shown as mean ± SEM of R3 independent experiments unless indicated.
dent’s t test or ANOVA test, where indicated. Comparison among multiple grou
comparison using Tukey test. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.ulation during activation promotes SRC in TM cells generated
in vitro with IL-15 (Figure 1A) and is also required for the gener-
ation of functional TM cells in vivo (Klein Geltink et al., 2017).
We analyzed lipids from interleukin (IL)-15 TM cells activated
with aCD3 or with aCD3/aCD28 and observed higher CL72:8
and CL72:6 (Figure 1B) as well as total CL content (Figure 1C)
in cells activated with CD28 co-stimulation. Nutrient restriction
also induces CD28-dependent mitochondrial elongation in
CD8+ T cells (Klein Geltink et al., 2017) and the assembly of
ETC supercomplexes in order to sustain viability and protect
from cell death (Gomes et al., 2011). Thus, we generated
in vitro IL-2 TE cells and cultured them in 1 mM versus 10 mM
glucose for 20 h before analyzing lipid composition. Culturing
IL-2 TE cells in 1 mM glucose for 20 h generated higher SRC (Fig-
ure 1D) (Klein Geltink et al., 2017). Lipidomics analysis revealed
that various CL species were significantly enriched in 1 mM
glucose (Figure 1E), increasing overall CL content (Figure 1F).
We obtained similar results culturing IL-2 CD8+ TE cells in a me-
dium containing 10 mM galactose (instead of glucose) to force
mitochondrial respiration (Chang et al., 2013) (data not shown).
Of note, the metabolic rewiring that led to increased CL content
(Figures 1B–1F) occurred without an increase in mitochondrial
mass measured by TOM20 andMnSOD, ETC protein levels (Fig-
ures 1G, 1H, S1A, and S1B), MitoTracker Green dye accumula-
tion (Figures 1I and 1J), and mtDNA/nuclear DNA (nDNA) ratio
(Figures S1C and S1D). De novo CL synthesis in the 1 mM con-
dition was needed to generate higher SRC and protect cells from
starvation-induced death as these cells lost SRC (Figure 1K) and
viability (Figure 1L) when treated with the PTPMT1-specific in-
hibitor alexidine dihydrochloride (AD).
In vitro generated IL-15 TM cells are characterized by higher
SRC (Figure 1M) as well as by elongated mitochondria together
with greatermitochondrial mass (Buck et al., 2016; van derWindt
et al., 2012). These cells also displayed a selective enrichment
in CL (Figures 1N, 1O, and S1E), accompanied by higherog2FC and p value calculated with ANOVA test.
ose restriction.
lucose restriction.
d in complete medium until day 3, then for additional three days in IL-2 (IL-2 TE)
g2FC and p value calculated with ANOVA test.
ted ex vivo fromC57BL/6mice. Data show Log2FC and p value calculated with
ividual mice.
entiated into IL-15 TM cells in presence of
13C-glucose. At indicated time points
ntiated into IL-15 TM cells for 72 h in the presence of
13C-glucose or 13C-linoleic
bons traced into CL 72:8.
otopologue distribution of 13C-glucose and 13C-linoleic acid-derived carbons
Statistical comparisons for two groups calculated by unpaired two-tailed Stu-
ps (in [R] and [S]) calculated by One-Way ANOVA and correcting for multiple
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Figure 2. Cardiolipin Is Necessary for In Vivo and In Vitro CD8+ T Cell Responses
(A) Schematic of the cardiolipin synthesis pathway.
(B) PTPMT1 expression in CD8+ T cells from PTPMT1 WT (Ptpmt1flox/floxCD4-Cre/) and PTPMT1-DT (Ptpmt1flox/floxCD4-Cre+/) mice.
(legend continued on next page)
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OPEN ACCESSArticleexpression of PTPMT1 and CRLS1 (Figure S1F), as compared to
what was seen in IL-2 TE cells. Although there was up to a 1.5-/2-
fold difference in mitochondrial mass observed between IL-2 TE
and IL-15 TM cells (considering mtDNA/nDNA ratio or TFAM
expression; van der Windt et al., 2012), the CL amount increased
almost three times, suggesting a specific enrichment in CL in the
mitochondria of IL-15 TM cells. In vitro culture and in vivo differ-
entiation of T cells could be different (Ma et al., 2019). Therefore,
we sorted CD8+ T effector memory (TEM CD62L
loCD44hi) and
CD8+ T central memory (TCM CD62L
hiCD44hi) cells from the
same animal and analyzed their lipid composition. Lipidomics
analysis showed CL 72:8 among the most significantly enriched
lipids (Figures 1P and S1G) and almost exclusively responsible
for the increase in total CL mass in CD8+ TCM cells (Figure 1Q).
Notably, human (h) CD8+CD45RO+ TEM cells also had a higher
basal and maximal respiration rate than did hCD8+CD45RA+
naive T (TN) cells (Figure S1H). They also exhibited, although
with higher variability, a trend toward the enrichment of specific
CL species (Figure S1I) and higher total CL content (Figure S1J),
without major changes in mitochondrial mass (Figure S1K).
Taken together these data suggest that T cells, upon stimuli
that provoke mitochondrial respiration (e.g., CD28 co-stimula-
tion, glucose restriction, galactose culture, or IL-15 supported
TM cell development), rewire metabolism to increase mitochon-
drial efficiency through de novo cardiolipin synthesis before, or
independently from, mitochondrial biogenesis.
Substrate Utilization Reveals ActiveDeNovoCardiolipin
Synthesis andRemodeling during TMCell Differentiation
To gain insight into the metabolic rewiring responsible for the in-
crease in CL content in IL-15 TM cells, we performed
13C-glucose
and 13C-linoleic acid tracing to measure incorporation of labeled
carbons into CL. The first was used to measure whether the
classic energetic substrate of IL-15 TM cells was used for de
novo CL synthesis (O’Sullivan et al., 2014), the latter to investi-
gate CL remodeling by the acyltransferase TAFAZZIN, whose(C) Cardiolipin content in freshly isolated Ptpmt1 WT and Ptpmt1/ CD8+ T cell
(D) Percentage of CD8+ T cells in spleens from PTPMT1 WT and PTPMT1-DT m
(E) PTPMT1WT and PTPMT1-DT mice infected i.v. with 13 106 colony-forming u
after primary infection. Blood analyzed at indicated time.
(F) Percentage of CD8+ T cells in PTPMT1 WT and PTPMT1-DT mice infected as
(G) Percentage of CD8+ Tet+ T cells in PTPMT1 WT and PTPMT1-DT mice infect
(H) Bacterial burden shown as CFU per mg of liver of PTPMT1 WT and PTPMT1-D
(I) TN (CD62L
hiCD44lo), TE (CD62L
loCD44hi), and TM (CD62L
hiCD44hi) CD8+ T cells
represent individual mice.
(J) EEC, SLEC, MPEC, and DPEC CD8+ T cells from PTPMT1 WT and PTPM
expression. Dots represent individual mice.
(K) OCR/ECAR ratio of WT and Ptpmt1/ CD8+ T cells analyzed 7 days after se
(L) Ptpmt1 WT and Ptpmt1/ CD8+ T cells stimulated with PMA/Iono for 4 h. Als
cytokine-producing cells.
(M) Cytoplasmic calcium levels at baseline and after aCD3 crosslinking via IgG, ta
Representative of 3 experiments.
(N) CD5, CD44, CD25, and CD69 expression in Ptpmt1 WT and Ptpmt1/ CD8+
(O) Survival of Ptpmt1 WT and Ptpmt1/ CD8+ T cells 24 h after activation.
(P) Cell cycle analysis assessed by FxCycle + Ki67 staining of Ptpmt1 WT and P
(Q) Active proliferation assessed by Ki67 expression in Ptpmt1 WT and Ptpmt1
(R) Cell proliferation assessed by CTV dilution of Ptpmt1WT and Ptpmt1/CD8+
of 4 independent experiments.
Data shown asmean ± SEM ofR3 independent experiments unless indicated. Sta
test, *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S2.main substrate is linoleic acid. Given the large number of car-
bons in a CL molecule (81 for a CL 72:8), it was not surprising
to measure a natural occurrence of a few 13C atoms in a non-
exogenously labeled molecule (Figures 1R and S1L, untreated
samples, 0 % M % 3). Thus, we considered isotopologues
with a mass of MR +4 as a cut-off for our analysis (dashed line
in Figures S1L and S1M). In IL-15 wild-type (WT) CD8+ TM cells
cultured with 13C-glucose, almost all the newly synthesized CL
contained glucose-derived carbons (Figures 1R and S1L). We
next treated cells cultured in IL-15 plus 13C-glucose or 13C-lino-
leic acid for 72 h with or without AD to inhibit de novo CL synthe-
sis during TM differentiation. The data showed that both glucose-
and linoleic-acid-derived 13C accumulated efficiently in newly
synthesized CL (Figures 1S and S1M) and revealed the differen-
tial molecular origin of carbon incorporation (Figures 1S, 1T,
S1M, and S1N). When normalized to total CL, the percentage
of MR +4 CL was reduced by AD only in cells cultured in 13C-
glucose (Figure 1T), suggesting that glucose-derived carbons
are incorporated through PTPMT1-dependent de novo CL syn-
thesis, whereas linoleic acid molecules are incorporated into
CL through active remodeling of CL (substitution of CL acyl
chains), a process not affected by AD during TM generation
(Figure S1N).
Cardiolipin Is Essential for In Vivo and In Vitro CD8+ T
Cell Responses
CL is synthesized in a two-step reaction in which phosphati-
dylglycerophosphate (PGP) is dephosphorylated by the mito-
chondrial phosphatase PTPMT1 into phosphatidylglycerol
(PG) then fused to another diacylglycerol molecule (DAG) to
generate CL by CRLS1(Zhang et al., 2011) (Figure 2A). To
investigate the physiological relevance of CL in T cells, we
crossed mice carrying floxed alleles of Ptpmt1 with mice ex-
pressing CD4-Cre to selectively ablate Ptpmt1 in T cells
(Ptpmt1flox/floxCD4-Cre mice are referred to as PTPMT1
WT, Ptpmt1flox/floxCD4-Cre+ as PTPMT1-DT) (Figure 2B).s.
ice. Dots represent individual mice.
nits (CFU) LmOVA DActa and challenged i.v. with 53 107 CFU LmOVA 21 days
in (E). Dots represent individual mice.
ed as in (E). Dots represent individual mice.
T mice 7 days post-LmOVA DActa challenge. Dots represent individual mice.
from PTPMT1 WT and PTPMT1-DT mice 7 days after primary infection. Dots
T1-DT mice 7 days after primary infection according to KLRG1 and CD127
condary infection. Dots represent individual mice.
o shown is the percentage of CD8+ T cells producing IFN-g and IFN-g MFI of
psigargin (TG), and ionomycin (iono) in Ptpmt1WT and Ptpmt1/CD8+ T cells.
T cells 24 h after activation with aCD3/aCD28 + IL-2.
tpmt1/ CD8+ T cells 24 h and 48 h after activation with aCD3/aCD28 + IL-2.
/ CD8+ T cells 24 h and 48 h after activation with aCD3/aCD28 + IL-2.
T cells 72 h after activation with aCD3/aCD28 + IL-2. Histogram representative
tistical comparisons for 2 groups calculated by unpaired two-tailed Student’s t
Cell Metabolism 32, 981–995, December 1, 2020 985
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OPEN ACCESS ArticleLower amount of total CL (Figure 2C) and a reduction in CL
72:8 and CL 72:6 species (Figure S2A) confirmed the effective
inhibition of CL synthesis in Ptpmt1/ CD8+ T cells. CD8+ TN
cells from PTPMT1-DT mice showed no major differences in
expression of subunits of ETC complexes, TOM20, or OPA1
in comparison with PTPMT1 WT cells (Figure S2B). PTPMT1-
DT mice had grossly normal thymic development (Figure S2C)
but peripheral lymphopenia with altered frequencies and
numbers of TCRb CD8+ and CD4+ (Figures 2D, S2D, and
S2E) and TCRgd CD8+ and CD4+ T cells (Figures S2F and
S2G) in multiple organs.
To assess the effect of CL deficiency during CD8+ T cell re-
sponses in vivo, we infected PTPMT1 WT and PTPMT-DT mice
with a sublethal dose of attenuated L. monocytogenes express-
ing Ova (LmOVA DActa) and then followed the total, as well as
the Ova-specific CD8+ T cell response, for 3 weeks before chal-
lenging the mice with a higher dose of bacteria to evaluate recall
responses and protective immunity. Although PTPMT1 WTmice
mounted a primary CD8+ T cell response that peaked 7 days
post-infection and an enhanced secondary response after chal-
lenge, PTPMT-DT mice failed to do so, mounting only a very
limited Ova-specific response after secondary immunization
(Figures 2E–2G). This defect resulted in the persistence of
bacteria in the liver of PTPMT1-DT mice after secondary
challenge (Figure 2H). A significantly higher proportion of TN
(CD62LhiCD44lo) compared to TE (CD62L
loCD44hi) cells (Figures
2I) as well as a higher proportion of early TE cells (EECs,
KLRG1loCD127lo) compared to short-lived TE cells (SLECs,
KLRG1hiCD127lo) and memory precursor TE cells (MPECs,
KLRG1loCD127hi) (Figure 2J) was present in PTPMT1-DT mice
7 days post-infection, suggesting impaired T cell activation.
Consistent with the role of CL in regulating cristae organization
and OXPHOS efficiency, Ptpmt1/ CD8+ T cells isolated
7 days post-challenge exhibited a lower OCR/ECAR (oxygen
consumption rate/extracellular acidification rate) ratio relative
to WT counterparts (Figure 2K).
The failure of Ptpmt1/ CD8+ T cells to expand upon
infection could be caused by defective T cell activation, a
proliferative defect due to impaired mitochondrial biogenesis
needed to keep up with cell division or increased cell death.
We also found impaired interferon (IFN)-g production in
freshly isolated Ptpmt1/ CD8+ T cells (Figure 2L). This
defect was not due to differential cytoplasmic calcium
handling, which was grossly similar between Ptpmt1 WT
and Ptpmt1/ CD8+ T cells upon T cell receptor (TCR) acti-
vation (Figure 2M). CD69, CD44, and CD25 expression 24 h
after aCD3/aCD28 activation was higher in Ptpmt1/ CD8+
T cells (Figure 2N), corroborating the observation that the sig-
nals that drive early T cell activation were normal, at least by
surface-marker expression. At the same time point, there was
no sign of increased TCR stimulation-dependent apoptosis
(Figure 2O). Nevertheless, CL-deficient CD8+ T cells dis-
played a marked defect in cell cycle entry and progression
at 24 h and 48 h post-activation measured by DNA content
(Figure 2P) and Ki67 expression (Figure 2Q), resulting in
impaired proliferation 72 h post-activation (Figure 2R).
Comprehensively, these data suggest that CL is required for
T cell cytokine production, cell cycle entry, and proliferation
upon in vitro and in vivo antigen challenge.986 Cell Metabolism 32, 981–995, December 1, 2020Unlike CD8+ IL-2 TE Cells, CD8
+ IL-15 TM Cells Require
PTPMT1 for Survival and Cytokine Production
To assess whether the differences in activation and proliferation
(Figures 2L–2R) would affect in vitro IL-2 TE or IL-15 TM cell dif-
ferentiation, we activated Ptpmt1 WT and Ptpmt1/ CD8+
T cells for 3 days and then differentially cultured them in IL-2 or
IL-15 to generate TE-like cells or TM-like cells, respectively.
Ptpmt1/ IL-15 TM cells showed a strong defect in survival (Fig-
ure S2H) and lower CD62L expression (Figure S2I) and IFN-g
production upon restimulation (Figure S2J) than did Ptpmt1
WT IL-15 TM cells. Ptpmt1
/ IL-2 TE cell properties were largely
unaffected with the exception of the persistent proliferative
defect (Figures S2H–S2K). Lower mitochondrial membrane po-
tential was observed both in IL-2 TE and IL-15 TM cells (Fig-
ure S2L, upper panel), whereas mitochondrial mass was unal-
tered (Figure S2L, lower panel). The metabolic deficiencies in
Ptpmt1/ IL-15 TM cells were further highlighted by the absence
of SRC (Figure S2M) and defective maximal glycolytic rate
(Figure S2N).
Metabolic Reprogramming upon CD8+ T Cell Activation
Requires Cardiolipin, but Not Its De Novo Synthesis
We found that CL is necessary for CD8+ T cell responses both
in vitro and in vivo (Figure 2). Yet, whether CD8+ T cells needed
de novo CL synthesis early during activation was not clear. We
activatedWTCD8+ T cells in the presence of the CL synthesis in-
hibitor AD during the first 48 h of stimulation, thenwashed out AD
and differentiated the cells in IL-15 (Figure S3A). Lipidomics
analysis of cells 48 h after activation, at the moment of AD
wash out, showed no difference in total CL content with un-
treated cells (Figure S3B), although some changes were
observed in the CL species profile (Figure S3C). Cells from the
same experiment analyzed 3 days post-IL-15 TM differentiation
showed no defects in basal or maximal respiration (Figure S3D)
or IFN-g production (Figure S3E). Then, we compared CL con-
tent of unstimulated cells with cells at different time points after
aCD3/aCD28 stimulation (Figure 3A). Total CL content remained
stable in the first 6 h after stimulation before strongly decreasing
at later time points (Figure 3B). Of note, this drop occurred before
the first cell division and without mitochondrial content dilution
(Figure S3F). The drop in total CL was also paralleled by changes
in acyl-chain composition (Figure 3C). CL 72:6 started to in-
crease 24 h post-activation (Figure 3C). This observation would
suggest that CL 72:6 could be the first CL species to be gener-
ated when the process of CL synthesis is re-activated, followed
by CL 70:8, CL 70:6, and CL 72:9, whose increased levels are
blunted by AD treatment during 48-h activation (Figures 3C
and S3C). Overall, these results suggest that de novo synthesis
of CL is not necessary for T cell priming and that its inhibition dur-
ing early activation does not affect in vitro TM cell differentiation
later on.
Even though de novo synthesis of CL is not necessary for T cell
activation the presence of a threshold level of CL is required for
in vivo and in vitro immune responses (Figure 2). Considering the
metabolic reprogramming that characterizes CD8+ T cells upon
activation (Buck et al., 2017), we hypothesized that during anti-
gen stimulation CL might maintain efficient mitochondrial
metabolism, thus promoting proper T cell activation. To test











Figure 3. Metabolic Reprogramming upon CD8+ T Cell Activation Requires Cardiolipin, but Not Its De Novo Synthesis
(A) Schematic of CD8+ T cells activated with aCD3/aCD28 +IL-2. At indicated time points cell pellets were collected for lipidomics analysis.
(B) Total CL amount in CD8+ T cells treated as in (A)
(C) Cardiolipin species in CD8+ T cells treated as in (A).
(D) Schematic of WT CD8+ T cells activated with aCD3/aCD28 +IL-2 with ± AD.
(E) Cytokine production of WT CD8+ T cells activated as in (D) analyzed at indicated time points.
(F) Schematic of WT and Ptpmt1/ CD8+ T cells activated with aCD3/aCD28 + IL-2.
(G) Cytokine production of WT and Ptpmt1/ CD8+ T cells activated as in (F) analyzed at indicated time points.
(H) WT CD8+ T cells activated with aCD3/aCD28 + IL-2 in a medium containing 10mM 13C-glucose ± AD. Twenty-four h after activation cell pellets were collected
for metabolomics analysis.
(I) WT and Ptpmt1/ CD8+ T cells activated with aCD3/aCD28 + IL-2 in a medium containing 10mM 13C-glucose. Twenty-four h after activation cell pellets were
collected for metabolomics analysis.
(J) 13C-glucose derived carbons incorporated into indicated metabolites in WT CD8+ T cells treated as in (H). Data represent mean ± SEM of 3 samples per
genotype.
(K) 13C-glucose derived carbons incorporated into indicated metabolites in Ptpmt1WT and Ptpmt1/ CD8+ T cells treated as in (I). Data represent mean ± SEM
of 3 samples per genotype.
(L) Schematic of 13C-glucose tracing experiment results in WT CD8+ T cells ± AD, Ptpmt1 WT, and Ptpmt1/ CD8+ T cells.
Data shown asmean ± SEM ofR3 independent experiments unless indicated. Statistical comparisons for 2 groups calculated by unpaired two-tailed Student’s t
test, *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S3.
ll
OPEN ACCESSArticle




K Q R S T
L
M N O P
C D F G H
E
Figure 4. Cardiolipin Synthesis Supports CD8+ TM Cell Development, Metabolism, and Function
(A) Schematic of CD8+ T cells activated with aCD3/aCD28 + IL-2 for 48 h and then cultured ± AD for 72 h during IL-15 TM cell development.
(B) Quantification of total CL content in IL-15 TM cells cultured as in (A).
(C) OCR of IL-15 TM cells cultured as in (A) at baseline and after exposure to aCD3/aCD28 coated beads, Oligo, FCCP, and Rot/Ant.
(D) IL-15 TM cells were cultured as in (A) and then restimulated with aCD3/aCD28 for 20 h. Percentage of producing IFN-g cells, and IFN-g MFI are shown.
(E) Schematic of the activation of CD8+ T cells isolated from Ptpmt1flox/floxErt2-Cre/ (PTPMT1 iWT) Ptpmt1flox/floxErt2-Cre+/ (PTPMT1 iDT) mice and 4-OHT
treatment.
(F) CL content in Ptpmt1 iWT and Ptpmt1 iDT CD8+ T cells cultured as in (E).
(G) OCR of Ptpmt1 iWT and Ptpmt1 iDT CD8+ T cells cultured as in (E) at baseline and after exposure to PMA/Ionomycin, Oligo, FCCP, and Rot/Ant.
(H) Ptpmt1 iWT and Ptpmt1 iDT CD8+ T cells cultured as in (E) and stimulated with aCD3/aCD28 for 20 h. Percentage of producing IFN-g cells and IFN-g MFI
are shown.
(I) Schematic of WT CD8+ T cells activated with aCD3/aCD28 + IL-2 for 48 h, cultured additional 24 h in IL-2 before performing Ctrl/Ptpmt1 CRISPR. 24 h after
CRISPR, equal number of CRISPR Ctrl/Ptpmt1 KO cells were transferred in congenic recipient mice and donor cell frequencies followed for 21 days before
LmOVA WT infection.
(J) Percentage of CD8+ CD45.2+ Tet+ CRISPR Ctrl/Ptpmt1 KO cells treated as in (I), shown as mean ± SEM.
(K) Bacterial burden shown as CFU per mg of liver isolated from mice treated as in (I) 3 days post-LmOVA challenge. Dots represent individual mice.
(L) Schematic of WT CD8+ T cells activated and cultured in IL-2 in the presence of BSA-conjugated 50 mM PG(18:1)2 or 50 mM PG(18:2)2 for 48 h.
(M) Quantification of CL species in IL-2 TE CD8
+ T cell cultured ± PG(18:2)2 for 48 h.
(N) Maximal cristae width measured in IL-2 TE CD8
+ T cell cultured as in (M).
(O) SRC of IL-2 TE CD8
+ T cells cultured as in (M) stimulated with aCD3/aCD28 coated beads.
(P) Cytokine production (normalized to untreated cells) measured in IL-2 TE CD8
+ T cells activated as in (M) and stimulated for 20 h with aCD3/aCD28 + IL-2.
(Q) Schematic of adoptive transfer strategy of OT-I IL-2 CD8+ TE cells—pre-treated as in (L)— into congenic recipient mice. Twenty-one days post-transfer, mice
were infected i.v. with 1 3 106 CFU of LmOVA DActa.
(R) Survival of donor cells 21 days post-transfer, expressed as number of donor cells in the spleen. Dots represent individual mice.
(S) Percentage of circulating donor cells 21 days post-transfer. Dot represent individual mice.
(T) Number of donor cells recovered from spleens of recipient mice 5 days after infection with LmOVA DActa. Dots represent individual mice.
(legend continued on next page)
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with or without AD during activation, as well as ofPtpmt1WTand
Ptpmt1/ CD8+ T cells. WT cells were fully equipped with CL,
and only de novo synthesis was pharmacologically inhibited. In
Ptpmt1/ CD8+ T cells, as a result of lacking PTPMT1 and de
novoCL synthesis, the cells were CL deficient. Cytokine produc-
tion was tested at different time points post-activation (6 h, 24 h,
and 48 h) (Figure 3D). Although pharmacological inhibition of
PTPMT1 by AD did not affect cytokine production (Figures 3D
and 3E), Ptpmt1/ CD8+ T cells showed a marked reduction
in IFN-g and tumor necrosis factor (TNF) production with unal-
tered IL-2 synthesis (Figures 3F and 3G). Then, we traced 13C-
glucose during the first 24 h post-aCD3/aCD28 stimulation in
WT CD8+ T cells cultured with or without AD and in Ptpmt1 WT
and Ptpmt1/ CD8+ T cells (Figures 3H and 3I). Both WT
CD8+ T cells incubated with or without AD (Figures 3J and
S1G–S1I) and Ptpmt1 WT and Ptpmt1/ T cells (Figures 3K
and S3L–S3N) acquired glucose equally and then metabolized
it to pyruvate and lactate to the same extent. However, although
pyruvate entered the tricarboxylic acid (TCA) cycle and 13C car-
bons were incorporated into TCA cycle intermediates in both in
WT CD8+ T cells incubated with or without AD (Figures 3J,
S1J, and S1K) as well as in Ptpmt1WT control CD8+ T cells (Fig-
ures 3K, S3O, and S3P), it was preferentially shunted to alanine
with decreased incorporation into TCA cycle intermediates in
Ptpmt1/ T cells (Figure 3L). Consistent with the role of PTPMT1
in modulating SDH function (Nath et al., 2015), AD-treated WT
cells had lower levels of 13C-glucose-derived carbon incorpora-
tion into fumarate (Figure 3J). These results highlight that CD8+
T cells require basal levels of CL, but not its de novo synthesis,
to allow metabolic activation upon TCR triggering.
Cardiolipin Synthesis Supports CD8+ TM Cell
Development, Metabolism, and Function
PTPMT1-DT mice allowed us to investigate the role of de novo
CL synthesis in T cell responses in vivo. However, this mouse
model produced T cells deficient for Ptpmt1 from embryonic
development and therefore did not allow us to test the role of
de novo CL synthesis exclusively in TM development. We
tackled this question from multiple angles by using pharmaco-
logical inhibition (Figure 4A), inducible genetic deletion (Figures
4E), and a CRISPR approach (Figure 4I). Inhibition of PTPMT1
with AD during IL-15 TM differentiation (Figure 4A) reduced total
CL content (Figure 4B) by additive reduction of the most abun-
dant CL species in CD8+ T cells (Figure S4A). AD worked selec-
tively on CL, because variations in other lipids were limited (Fig-
ure S4A). CL synthesis is a slow process, and IL-15 TM cells did
not show alterations in OCR upon direct AD treatment (Fig-
ure S4B). Mitochondrial mass (Figure S4C, left panel) or ETC
complex levels were not altered (Figure S4C, right panel),
although AD treatment induced accumulation of short forms
of OPA1 (Figure S4C, right panel), commonly observed during
mitochondrial fission (Ban et al., 2017; Cipolat et al., 2006; Co-
gliati et al., 2013). We previously described how TM cells have
tight cristae with closely associated ETC complexes, whichData shown asmean ± SEM ofR3 independent experiments unless indicated. Sta
test, *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.renders their mitochondrial membranes less susceptible to
digitonin disruption than those of TE cells (Buck et al., 2016).
Hypothesizing that CL might play a key role in this process,
we performed a similar experiment where untreated or AD-
treated IL-15 TM cells were incubated with increasing concen-
trations of digitonin followed by separation of the crude
membrane-bound fraction from solubilized proteins by centrifu-
gation. We found a greater proportion of ETC complex subunits
in the soluble fraction of AD-treated cells (Figure S4D), indi-
cating that ETC complexes were more loosely embedded in
the IMM or that the protein/lipid ratio was altered, because
the membranes were more susceptible to digitonin disruption
when CL synthesis was inhibited. Electron micrographs of un-
treated and AD-treated IL-15 TM cells further confirmed cristae
structure alterations with increased maximal cristae width (Fig-
ure S4E), and live-cell imaging revealed mitochondrial fragmen-
tation (Figure S4F) upon CL synthesis inhibition. In vitro IL-15
TM rely on OXPHOS to meet their energetic needs (Buck
et al., 2017). In line with this, only IL-15 TM cells exhibited a sur-
vival defect when CL synthesis was inhibited (Figure S4G).
Furthermore, AD treatment impaired CD62L expression (Fig-
ure S4H), SRC (Figure 4C), and IFN-g production (Figure 4D)
in IL-15 TM cells.
Although our data showed that AD selectively inhibited CL
synthesis (Figures 4B and S4A) to rule out the possibility of off-
target effects of the drug we crossed a tamoxifen (4-OHT) induc-
ible (Ert2-CRE) mouse to the Ptpmt1flox/flox mouse to generate a
strain (Ptpmt1 iDT) whose cells could be inducibly deleted of
Ptpmt1 upon exposure to 4-OHT in vitro. To avoid any effect
on activation and early differentiation, we induced Ptpmt1 dele-
tion in vitro only during TM cell differentiation in IL-15 (Figures 4E
and S4I), without a reduction in Crls1 and Tafazzin (Taz) expres-
sion levels (Figure S4I). Ptpmt1 iDT cells recapitulated results
from AD-treated cells showing lower CL content than in
Ptpmt1flox/floxErt2-Cre (Ptpmt1 iWT) T cells subjected to the
same 4-OHT treatment (Figure 4F). IL-15 Ptpmt1 iDT cells also
showed a survival defect and a lower CD62L expression (Figures
S4J), SRC (Figure 4G), and IFN-g production (Figure 4H) than did
Ptpmt1 iWT T cells (Figure S4K).
Finally, to test the role of PTPMT1 in vivo during TM cell gener-
ation, we used a CRISPR approach. We activated OT-I cells
in vitro and deleted Ptpmt1 only at the peak of effector phase
(3 days post-activation), which allowed normal T cell activation
and expansion prior to deleting Ptpmt1. After an additional 24
h, we transferred an equal number of CRISPR Ctrl and CRISPR
Ptpmt1 knockout (KO) cells into congenic mice and tracked
donor cells for 21 days before LmOVA infection (Figure 4I).
CRISPR Ptpmt1 KO cells exhibited lower survival in vivo during
the TE cell contraction phase (Figure 4J). Strikingly, when mice
were then infected with LmOVA, only CRISPR Ctrl cells
expanded, whereas CRISPR Ptpmt1 KO cells failed to do so
(Figure 4J). As a result, only CRISPR Ctrl cells were able to effi-
ciently clear bacteria from the liver of infectedmice (Figure 4K). In
summary, PTPMT1 and CL synthesis support CD8+ TM cell gen-
eration both in vitro and in vivo.tistical comparisons for 2 groups calculated by unpaired two-tailed Student’s t
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Generation of Memory-like CD8+ T Cells
T cells with elongated mitochondria and tight cristae are more fit
in adoptive cellular immunotherapy models in mice (Buck et al.,
2016). We asked whether increasing CL content, which could
promote cristae tightness, would also have a similar effect on
T cell fitness. To increase CL content we supplemented IL-2 TE
and IL-15 TM cells with different forms of the CL precursor phos-
phatidylglycerol (PG), i.e., PG(18:2)2 and PG(18:1 D9-cis)2, for
48 h (Figure 4L). We found that, without affecting the overall lip-
idome (Figure S4L), only PG(18:2)2 increased total CL content as
well as CL 72:6 and CL 72:8 in both IL-2 TE and IL-15 TM cells
(Figures 4M and S4M–S4O). PG(18:1)2 did not increase total
CL or the main CL forms containing oleic acid CL 72:4, Cl 72:5,
and CL 70:4 (data not shown). The higher CL content observed
in IL-2 TE cells, although not sufficient to counteract mitochon-
drial fragmentation (Figure S4P), tightened cristae (Figures 4N
and S4Q) and resulted in higher SRC (Figure 4O), and increased
IFN-g, TNF production (Figure 4P), and expression of CD25 and
CD62L (Figure S4R). The further increase in CL content in IL-15
TM cells mediated by PG(18:2)2 (Figure S4M) did not induce
changes in surface marker expression (Figure S4R), SRC (Fig-
ure S4S), or cytokine production (Figure S4T), suggesting the ex-
istence of a maximal threshold for CL content to modulate T cell
function. To investigate whether these observations held true
in vivo, we adoptively transferred untreated and PG(18:2)2-
treatedOT-I IL-2 TE cells into congenicmice and tracked cell sur-
vival and responses against LmOVA DActa infection (Figure 4Q).
There were no differences in the number of donor cells in the
spleen (Figure 4R), with only a trend toward more circulating
PG(18:2)2-treated cells 21 days post-cell transfer (Figure 4S),
suggesting no difference in long-term survival between the two
populations. However, 5 days after LmOVA DActa infection, a
greater number of PG(18:2)2-treated cells were recovered in
the spleen of infectedmice (Figure 4T). These data raise the pos-
sibility that higher CL content protects cristae structure upon re-
stimulation, limiting cytochrome c release and activation-
induced cell death (AICD) (Corrado et al., 2016). Of note,
PG(18:2)2 supplementation in the context of 4-OHT-induced
deletion of Ptpmt1 in IL-15 TM cells (Figure S4U) did not rescue
CL content (Figure S4V), survival (Figure S4W), or cytokine pro-
duction (Figure S4X), likely reflecting inefficient incorporation of
external PG into CL in the absence of PTPMT1 (Serricchio
et al., 2018). Collectively, these data show that enhancing CL
content in vitro and in vivo generates T cells that are metaboli-
cally and functionally fit.
CD8+ T Cell Defects Observed in TAZ KO Mice Are Not
Intrinsic to CD8+ T Cells
Given the functions of CL in CD8+ T cell biology outlined here, we
set out to investigate the role of Tafazzin in T cells in a mouse
model of Barth syndrome and in a small cohort of Barth syn-
drome patients. We analyzed CL content in CD8+ T cells isolated
from TafazzinKOmice (full-body deletion) (Figure 5A) at 20weeks
of age, when cardiomyopathy and muscle weakness start to
develop (Cadalbert et al., 2015). CL deficiency was not only
limited to muscles but also observed in CD8+ T cells of Tafazzin
KOmice (Figures 5B and 5C) together with a slight but significant
reduction in CD62LhiCD44hi TCM cells (Figure 5D). Upon in vitro990 Cell Metabolism 32, 981–995, December 1, 2020stimulation, Tafazzin KO CD8+ T cells produced less IFN-g (Fig-
ures 5E–5G) and proliferated less efficiently (Figure 5H). In addi-
tion, IL-15 TMCD8
+ TafazzinKOcells showed an accumulation of
short forms of OPA1, a reduction in CIII protein levels (Fig-
ure S5A), and altered expression of CD25 and CD62L (Fig-
ure S5B) in comparison with IL-2 TE cells.
To understand whether the T cell impairment observed in mice
with total body deletion of Tafazzin was CD8+ T cell intrinsic, we
generated Taz CRISPR KO OT-I cells and investigated, in vitro
and in vivo, the result of TAZ acute deletion on T cell activation,
expansion, and response to infection (Figure S5C). The absence
of TAFAZZIN (Figures S5D and S5E) did not change the overall
lipid profile (Figure S5F), CL amount (Figure S5G), or composi-
tion (Figure S5H) comparable to those of Ctrl CRISPR T cells
6 h post-activation in vitro, the same time point when we
observed alterations in CLs in WT cells (Figure 3C), as well as
the activation-induced expression of CD5, CD25, CD44, and
CD69 (Figure S5I). Thus, TAFAZZIN was dispensable for CD8+
T cell activation. To translate these observations in vivo, we
adoptively transferred Ctrl and Taz CRISPR KO OT-I cells into
recipient mice and followed their response to LmOVA infection
(Figure S5J). Despite Taz CRISPR KO CD8+ T cells showing a
defective switch from EEC to SLEC (Figures S5K and S5L)
(both after primary and secondary challenge), similar to what
observed in PTPMT1-DT mice (Figure 2J), CD62L and CD44
expression was similar (Figure S5M). Moreover, Taz CRISPR
KO cells responded to antigen stimulation similarly to Ctrl cells
and generated TM cells that efficiently expanded upon second-
ary infection (Figure S5J). As per TAZ function, 7 days post-sec-
ondary infection-sorted CD8+ OT-I Taz CRISPR KO OT-I cells
showed a reduced level of CL in comparison with WT cells (Fig-
ures S5N and S5O). Nevertheless, even increasing the window
between primary and secondary LmOVA challenge from 3weeks
to 2 months did not alter CD8+ T cell function but confirmed de-
fects in the EEC to SLEC transition (Figures S5Q–S5T). In both
experiments, Taz CRISPR KO CD8+ T cells cleared bacteria
from the liver of infected mice (Figures S5P and S5U). Overall,
these data suggest that the defects observed in the T cell
compartment of TAZ KO mice either are not CD8+ T cell intrinsic
or might derive from hematopoietic lineage developmental
alterations.
T Cell Defects in a Small Cohort of Barth Syndrome
Patients
We analyzed peripheral blood mononuclear cells (PBMCs) from
5 patients under the care of the NHS Barth syndrome Service
(Barth syndrome group average age 13 years, min 6 years,
max 28 years; healthy donor group average age 28 years, min
22 years, max 39 years) with pathology confirmed both by
MLCL/CL(18:2)4 ratio (Figure 5I) and TAFAZZIN sequencing
(data not shown). Patients that had undergone cardiac trans-
plantation, and hence were on immunosuppressive drugs,
were excluded from the analysis. We found that patients had
significantly lower relative frequencies of CD8+ T cells in PBMCs
than did healthy donors (Figure 5J), with no apparent differences
in the CD4+ T cell compartment (Figure S5V). Although no differ-
ences were detected in the expression of naive/memory
CD45RA and CD45RO (Figure S5W), nor in surface markers of







Figure 5. CD8+ T Cell Defects n Tafazzin-Deficient Mice and in a Small Cohort of Barth Syndrome Patients
(A) Immunoblot analysis of cell extracts from freshly isolated WT and Tafazzin KO CD8+ T cells.
(B) Lipids extracted from freshly isolated CD8+ T cells from 20-week old WT and Tafazzin KO. Data show Log2FC and p value calculated with ANOVA test.
(C) Total CL amount in freshly isolated CD8+ T cells from 20-week old WT and Tafazzin KO mice. Dots represent individual mice.
(D) TN (CD62L
hiCD44lo), TEM (CD62L
loCD44hi), and TCM (CD62L
hiCD44hi) CD8+ T cells from 20-week–oldWT and TafazzinKOmice. Dots represent individual mice.
(E–G) Representative flow cytometry analysis (E), percentage of IFNg producing CD8+ T cells (F), and IFN-gMFI of CD8+ IFN-g+ T cells (G) of freshly isolated CD8+
T cells from 20-weeks old WT and Tafazzin KO mice stimulated for 4 h with PMA/iono. Dots represents individual mice.
(H) Cell proliferation of CD8+ T cells from 20-week-old WT and Tafazzin KO mice 48 h after activation with aCD3/aCD28 + IL-2. Dots represent individual mice.
(I) Monolysocardiolipin/cardiolipin (18:2)4 ratio in healthy donors and Barth syndrome patients. Dots represent individual donors.
(J) Representative flow cytometry analysis and quantification of the percentage of CD8+ T cells in hPBMCs from healthy donors and Barth syndrome patients.
Dots represent individual donors.
(K) Representative flow cytometry analysis and quantification of IFN-g production of CD8+ T cells from healthy donors and Barth syndrome patients activatedwith
PMA/iono for 5 h. Dots represent individual donors.
Data shown as mean ± SEM of R3 independent experiments unless indicated. Statistical comparisons for two groups calculated by unpaired two-tailed Stu-
dent’s t test or Anova test, where indicated, *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.
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IFN-g production after stimulation (Figure 5K). Overall, our anal-
ysis suggests a possible CD8+ T cell impairment in patients
affected by Barth syndrome.
DISCUSSION
Although metabolic reprogramming during the adaptive im-
mune response has been widely explored in recent years, the
role of mitochondrial lipid composition and, in particular, CL
in this scenario remained uninvestigated. Our study shows
that the dynamic regulation of synthesis and remodeling of a
single lipid confers to T cell mitochondria the plasticity neces-
sary for adapting to the different metabolic and functional re-
quirements during all phases of the T cell response—from acti-
vation, to expansion, contraction, and eventually long-term
immune protection.
In the absence of CL, PTPMT1-DT mice mounted a defective
CD8+ T cell response upon infection. We found that de novo CL
synthesis was not necessary for T cell activation, but the pres-
ence of a sufficient initial pool of CL in the mitochondrial mem-
brane was required. Indeed, ex vivo-activated Ptpmt1/ CD8+
T cells were defective in cytokine production and metabolic
adaptation even before a proliferative defect emerged. During
activation the CL profile is modulated in human T cells (M€urke
et al., 2016), whereas inmurine CD4+ T cells stomatin-like protein
2 (SLP2) organizes CL in lipid rafts (Christie et al., 2012). Given
the interaction of CL with different subunits of the ETC, and the
burst in ROS during T cell activation (Dudek, 2017; Sena et al.,
2013), it is tempting to speculate that CL modifications/oxida-
tions are required for the metabolic shifts that occur during early
T cell activation and that Ptpmt1 ablation might alter ROS pro-
duction upon TCR triggering. It also remains to be determined
whether during antigen stimulation ROS causes CL oxidation
to instruct mitochondrial structural and metabolic reprograming
or whether ROS acts in a CL-independent manner.
Our lab previously showed thatOpa1-deficient T cells are able
to form TE cells after primary infection with a later failure in TM cell
generation (Buck et al., 2016). Here, we characterize how
Ptpmt1/ T cells have a broader defective phenotype, failing
to activate properly and expand into TE cells. Thus, whereas
OPA1 and CL might in part functionally share the role of main-
taining cristae structure, the different nature of a protein versus
a lipid, a specific signaling role for CL during T cell activation,
and amore structural requirement for CL synthesis for mitochon-
drial biogenesis during T cell expansion might contribute to the
differential cellular behavior of the two models.
When autophagy is triggered by low nutrient availability, mito-
chondria elongate to sustain viability and avoid starvation-
induced cell death (Buck et al., 2016; Gomes et al., 2011). This
change is accompanied by an increase in the number of cristae,
assembly of respiratory chain supercomplexes, and in the dimer-
ization and activity of the ATP synthase (Balsa et al., 2019;
Gomes et al., 2011). Here we show that upon glucose restriction,
cellular metabolism rapidly responds by synthesizing CL, inde-
pendently from changes in mitochondrial mass, thus increasing
SRC and limiting apoptosis. Of note, both these pro-survival fea-
tures are lost if de novo CL synthesis is inhibited during glucose
restriction. CL binds selectively but transiently to the ATP syn-992 Cell Metabolism 32, 981–995, December 1, 2020thase, affecting its supramolecular organization (Acehan et al.,
2011; Duncan et al., 2016; Mehdipour and Hummer, 2016), as
well as to complex I (Jussupow et al., 2019) and complex II
(Schwall et al., 2012), modulating their stability and function. Of
note, in our experiments the subunit levels of complex I and com-
plex II (NDUFB8 and SDHB, respectively) are modulated
together with CL during glucose restriction, or upon CD28 co-
stimulation, which also results in increased OXPHOS efficiency
and higher CL content.
Safeguardingmitochondrial integrity andmetabolism is instru-
mental in generating long-lived and fit TM cells (Buck et al., 2016).
Indeed, mitochondrial fusion-fission cycles allow the segrega-
tion and elimination of dysfunctional mitochondria through auto-
phagy (Pickles et al., 2018). Induction of autophagy sustains TM
cell development, whereas its inhibition combined with mito-
chondrial dysfunction contributes to AICD of short-lived TE cells
(Corrado et al., 2016; Puleston et al., 2014; Xu et al., 2014). We
show that de novo CL synthesis is required to increase mito-
chondrial metabolic capacity and allow AICD resistance during
TM cell differentiation. Thus, increasing CL content might
improve adoptive cellular immunotherapy, where a lack of
T cell persistence after transfer remains an issue (Restifo et al.,
2012; Tschumi et al., 2018).
Mutations in TAFAZZIN responsible for Barth syndrome alter
CL remodeling and reduce total CL content over time due to
the inability of cells to regenerate mature CL from MLCL
(Schlame et al., 2003). In the mouse gut, intraepithelial lympho-
cytes (IELs) maintain a controlled activation state that relies on
mitochondria through a TAFAZZIN-dependent CL remodeling
mechanism (Konjar et al., 2018). Although able to migrate to
the site of infection and produce cytokines, bone marrow
chimera-derived Tafazzin-deficient IELs are not able to restrict
E. vermiformis infection (Konjar et al., 2018). Here, we reinforce
these observations in a total body Tafazzin KO mouse model,
resembling more closely the human pathology where TAFAZZIN
inactivating mutations are not confined to the hematopoietic
compartment. In particular, experiments in TAZ KO mice sug-
gested that reduced number and impaired function of CD8+
T cells follow long-term systemic CL deficiency. In addition,
our CRISPR data support the idea that the T cell functional de-
fects observed in bone marrow chimera Tafazzin-deficient
mice, as well as in total body TAZ KO mice, might not be CD8+
T cell intrinsic or might derive from hematopoietic lineage devel-
opmental alterations.
Cardiomyopathy and neutropenia are life-threatening features
of Barth syndrome. Some Barth syndrome patients require car-
diac transplantation followed by lifelong immunosuppressive
drug treatment (Mangat et al., 2007). Our analysis of hPBMCs
from a limited number of Barth syndrome patients suggests
the possibility of a relative lymphopenia and functional impair-
ment in the CD8+ T cell compartment. However, more detailed
clinical studies to assess the absolute number, frequency, and
function of lymphocyte subsets in a larger number of patients
are required. Less efficient responses to T cell-mediated vac-
cines or lower susceptibility to acute organ rejection after heart
transplant in Barth syndrome patients compared to non-affected
age-matched individuals might be expected if our hypothesis
holds true. In our view it is possible that the adaptive immune
phenotype in these patients might exacerbate the impact of
ll
OPEN ACCESSArticleneutropenia in the susceptibility to infections by a combination of
the impaired activation, proliferation, and differentiation of
TM cells.
In conclusion, we describe the pivotal role of the dynamic
regulation of CL synthesis in modulating CD8+ T cell function
during the immune response, from activation to TM cell differ-
entiation. Absence of CL due to impaired synthesis (PTPMT1-
DT) or remodeling (Tafazzin KO) results in compromised CD8+
T cell function, although our data suggest the latter is not
CD8+ T cell intrinsic. Moreover, we propose modulation of
CL content and/or composition as a strategy to improve adop-
tive cell immunotherapy. Lastly, our findings suggest a poten-
tially unrecognized T cell impairment in Barth syndrome pa-
tients, broadening the spectrum of pathologic features of
Barth syndrome and prompting a further evaluation of immune
function in patients and in clinical trials targeting CL
modifications.
Limitations of study
Although our study shows that cardiolipin synthesis is regu-
lated during CD8+ T cell responses to infection, it addresses
neither the role of different CL species nor the regulation of
acyl chain modifications. It also remains to be determined
the role of cardiolipin oxidation and its interplay with ROS pro-
duction upon CD8+ T cell activation. Lastly, analysis of T cell
function in larger cohort of Barth syndrome patients and
epidemiological studies on susceptibility to acute organ rejec-
tion after heart transplant are necessary to further corroborate
our observations.
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EasySep Human CD45RO+ CD8+ T Cell
Isolation Kit
StemCell Technologies, Inc. Cat#19159
EasySep Human CD45RA+ CD8+ T Cell
Isolation Kit
StemCell Technologies, Inc. Cat#19258
High Capacity cDNA Reverse Transcription Kit Thermofisher Scientific Cat#4368814
iTaq Universa Probes Supermix Bio-Rad Cat#1725131
Pierce BCA protein assay kit Thermofisher Scientific Cat#23225
Experimental Models: Organisms/Strains
C57BL/6J mice Jackson laboratories RRID: IMSR_JAX:000664
PTPMT1 floxed mice Jackson laboratories RRID: IMSR_JAX:020775
PhAM mice Jackson laboratories RRID: IMSR_JAX:018397
OT-I mice Jackson laboratories RRID: IMSR_JAX:003831
CD45.1 congenic mice Jackson laboratories RRID: IMSR_JAX:002014
TAZ KO Dr. Douglas Strathdee N/A
Oligonucleotides
PTPMT1 sgRNA1 IDT Mm.Cas9.PTPMT1.1.AA
PTPMT1 sgRNA2 IDT Mm.Cas9.PTPMT1.1.AB
PTPMT1 sgRNA3 IDT Mm.Cas9.PTPMT1.1.AC
TAZ sgRNA1 IDT Mm.Cas9.TAZ.1.AA
TAZ sgRNA2 IDT Mm.Cas9.TAZ.1.AB
TAZ sgRNA3 IDT Mm.Cas9.TAZ.1.AC
TaqMan Gene expression Assay, Assay ID:
Mm00504978_m1 TAZ FAM-MGB
Applied Biosystem Cat#4448892
TaqMan Gene expression Assay, Assay ID:
Mm04225274_s1 Gene Symbol: ND1 FAM-MGB
Applied Biosystem Cat#4331182
TaqMan Gene Expression Assay, Assay ID:
Mm03024075_m1 Gene: Hprt, FAM-MGB
Applied Biosystem Cat#4351368
Recombinant DNA




Wave software version 2.4 Agilent http://www.agilent.com/cs/ContentServer?
c=Page&pagename=Sapphire/Page/HomePage
FlowJO FlowJO https://www.flowjo.com
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Erika L.
Pearce (pearce@ie-freiburg.mpg.de)
Materials Availability
This study did not generate new unique reagents
Data and Code Availability
This study did not generate datasetse3 Cell Metabolism 32, 981–995.e1–e7, December 1, 2020
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Cell Culture and Drug Treatment
Mouse Cells
CD8+ T cells were isolated from spleens of 8-10 week-old mice using the naive or bulk CD8+ T cell kit (Stem Cell technologies, Cat#
19858, 19853) according to the manufacturers protocol. Both male and female mice were used and within experiments mice
were age and sex matched. Sample size is indicated in the figure legends. Isolated T cells were activated using plate
bound aCD3 (5 mg/mL) (anti-mouse CD3, inVIVOMAb Cat# BE0002), in 1640 media supplemented with 10% fetal calf serum,
4mM L-glutamine, 1% penicillin/streptomycin, 100 U/mL hrIL-2 (Peprotech), 55 mM beta-mercaptoethanol, and ± 0.5 mg/mL soluble
aCD28 (anti-mouse CD28, inVivoMab Cat# BE0015) under 5% CO2, atmospheric oxygen, at 37
C in a humidified incubator. TE and
TM cell differentiation was performed as previously described (Buck et al., 2016). Briefly, media changes were performed from day
2 post activation and then daily up to day 6. For TE cell differentiation cells were incubated in 100 U/mL hrIL-2 (Peprotech), for TM cells
in 100U/mLmIL-15 (Peprotech). Where indicated cells were treated with vehicle control (DMSO or EtOH)) or 1 mMAlexidine dihydro-
chloride (AD, Sigma, A8986), 50 mM PG(18:2)2 (Cat# 840485), PG(18:1 D9-cis)2 (Cat# 840475), 5nM 4-OHT. For in vitro survival as-
says, cells were activated for 3 days as described, then cultured in either IL-2 at 5x104 cells/mL, or in IL-15 at 1x105 cells/mL in 96well
round bottom plates. Survival was analyzed by 7-AAD exclusion using flow cytometry.
Human Cells
Fresh buffy coats from healthy donors were kindly provided by the Institute for Transfusion Medicine and Gene Therapy, Medical
Center, University of Freiburg under approval by the ethical committee of the University of Freiburg. PBMCs from healthy donors
and Barth Syndrome patients were collected at University of Bristol in accordance with the Helsinki Declaration with approval
from the UK NHS Research Ethics committee (permit number 09/H0202/52). Age and sex of healthy donors provided by the Institute
for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg were blinded to the authors. Barth syndrome pa-
tients were males (Barth syndrome group average age 13 years, min 6 years, max 28 years; healthy donor group average age 28
years, min 22 years, max 39 years). Informed consent was provided by all patients, or by their parents, in the case of children. Human
CD45RA+ and CD45RO+ CD8+ T cells were isolated using CD8+ T cell kits (StemCell technologies, Cat# 19258, 19159). Researchers
were blinded to the identity of the donors, and age or sexmatching was not performed. Sample size is indicated in the figure legends.
Mice and Immunizations
C57BL/6J (RRID: IMSR_JAX:000664), PhAM (RRID: IMSR_JAX:018397), major histocompatibility complex (MHC) class I-restricted
OVA specific TCR OT-I transgenic mice (RRID: IMSR_JAX:003831), and CD45.1 congenic (RRID: IMSR_JAX:002014) mouse strains
were purchased from The Jackson Laboratory. PTPMT1 floxed (RRID: IMSR_JAX:020775) mice were a kind gift form Jack E. Dixon
(University of California, San Diego, CA). TAZ KO mice were generated and maintained at the University of Glasgow by D. Strathdee
under license approved by University of Glasgow Ethical Review Process and the UK Animal Procedures Committee London.
PTPMT1 floxed mice were crossed to CD4-Cre or tamoxifen inducible ERT2-Cre mice. Experimental studies including mice of the
PTPMT1 strain were approved by the Regierungspr€asidium Freiburg. All mice were maintained in C56Bl6/J background and were
the results in in-house matings. In all experiments including WT and KO mice, WT littermates from same breedings were used as
controls. All mice, apart from TAZ KO, were maintained at the Max Planck Institute of Immunobiology and Epigenetics and cared
for according to the Institutional Animal Use and Care Guidelines. Briefly, mice were maintained in IVC Tecniplast green line cages
withmax fivemice per cage, light cycle was 14/10 h, temperature 20-24C, humidity 45%–64%. Ssniff MZ-Ereich chow (Cat# V1185-
300) was provided ad libitum. Health monitoring program followed FELASA recommendations (Laboratory Animals 2014, Vol.
48(178-192). Briefly, germ free NMRI mice are used as bedding sentinels receiving dirty bedding from up to 100 other cages weekly
for threemonths before being tested for all pathogens and opportunists recommended in the guidelines.Within experiments, age and
sex matched mice were injected intravenously (i.v.) as indicated with a sublethal dose of 1x106 colony forming units (CFU) of recom-
binant L. monocytogenes expressing OVA deleted for actA (LmOVA DActa) for primary immunizations and challenged with 5x107
CFU for secondary immunizations. Where indicated, 3x104 CFU of L. monocytogenes expressing OVA WT were used for primary
infection and 1x106 for secondary immunization.
All mice were used for experiments between 8-10 weeks of age apart from TAZ KO mice that were 20 weeks old (time in which
pathology develops) and animals used for TEM and TCM cell sorting that were 20-month old (in order to obtain a sufficient proportion
of both TEM and TCM cells from the same animal, 20% and 40% respectively (in 2-month old mice TEM cells constituted only 5% of
total CD8+ T cells). For in vivo experiments male mice were used, for in vitro studies both sexes were used interchangeably (no in-
fluence or association of sex on the results was observed).
METHODS DETAILS
Bacterial Burden
Liver biopsies were weighed and homogenized in 1ml of PBS. 10 mL per serial dilution of the original homogenate was plated on a
Brain Heart infusion Broth (BHI, Sigma Cat# 53286) agar and incubated over night at 37C. One day later the number of colonies were
counted and normalized to the weight of the liver biopsy.Cell Metabolism 32, 981–995.e1–e7, December 1, 2020 e4
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For in vivo TM cell experiments, £1x10
4 OT-I+ CD8+ T cells/mouse from donor splenocytes were transferred intravenously (i.v.) into
congenic recipient mice. Blood or spleens were collected at indicated time points and analyzed by flow cytometry. For in vivo survival
experiments, 1-2x106 treated IL-2 TE cells (6 days post activation) cells/mouse were injected i.v. into naive congenic CD45.1 mice.
Cells were recovered at indicated time points from the spleen or lymph nodes and analyzed by flow cytometry.
Flow Cytometry
Fluorochrome-conjugated monoclonal antibodies were purchased from eBioscience, BD PharMingen, or Biolegend. Staining was
performed in 1%FBS/PBS for 30min on ice, dead cells were excluded with the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo
scientific). OVA-specific CD8+ T cells from spleen, lymph node, or blood were quantified after red blood cell lysis by direct staining
with H2-KbOVA257-264 (K
bOVA) MHC-peptide tetramers. For intracellular cytokine staining cells were reactivated with aCD3/aCD28
overnight or 50 ng/mL phorbol 12-myristate 13-acetate (PMA) + 500 ng/mL ionomycin (all Sigma) for 4 h and cultured in the presence
of Brefeldin A for 4 h prior to fixation using Cytofix Cytoperm (BDBioscience). MitoTracker and TMRM staining were performed ac-
cording to the manufacturer’s instructions (Life Technologies) using respectively 10nM and 2nM of Mitotracker Green and TMRM in
presence of 0.5 mM of Cysclosporine H. Cells were collected on Fortessa flow cytometers (BD Biosceince) and analyzed using
FlowJo software (FlowJo).
Confocal and Electron Microscopy Imaging
Spinning disk confocal and EM imaging was performed as described previously (Buck et al., 2016). Cells were activated as indicated
and transferred to glass bottom dishes (MatTek) coated with fibronectin(Sigma) in complete medium containing IL-2 or IL-15 using a
Zeiss spinning disk confocal with an Evolve (EMCCD) camera. Cells were kept in a humidified incubation chamber at 37C with 5%
CO2 during image collection. Confocal imaging was analyzed using Imaris imaging software. For Electron Microscope imaging 2 3
106 T cells were fixed in 2.5%glutaraldehyde in 100mM sodium cocodylate, washed in cocodylate buffer. After dehydration samples
were embedded in Eponate 12 resin (Ted Pella) and sections were cut. Images were acquired using a FEI Tecnai 12 Transmission
electron microscope equipped with a TIETZ digital camera. Cristae width was measured using ImageJ software and averaged
over 50 independent images, acquisition of EMmicrographs and measurements of max cristae width displayed were performed us-
ing ImageJ software (NIH). Brightness and contrast were adjusted in ImageJ software (NIH)
Metabolic Phenotyping
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured in XF media (non-buffered RPMI 1640
containing 25 mM glucose, 2mM L-glutamine, and 1 mM sodium pyruvate) under basal conditions and in response to 1 mMoligomy-
cin, 1.5 mMfluoro-carbonyl cyanide phenylhydrazone (FCCP) and 100 nM rotenone + 1 mMantimycin A, or 50 ng/mL phorbol 12-myr-
istate 13-acetate (PMA) + 500 ng/mL ionomycin (all Sigma) using a 96 well XF or XFe Extracellular Flux Analyzer (EFA) (Seahorse
Bioscience). 2 x105 T cells per well (33 wells per sample) were spun onto poly-D-lysine coated seahorse 96 well plates and preincu-
bated at 37C for a minimum of 45 min in the absence of CO2. For activation of T cells, aCD3 ± CD28 coated beads were used at 1:1
ratio of beads:T cell Thermofisher, Cat# 11452D). For metabolic tracing naive (TN) cells (Figure 4) were isolated and activated as
described above in glucose-free media supplemented with 11 mM D-[U13C] glucose or 11mM unlabeled D-glucose for 24 h. Cells
were washed with ice cold 0.9%w/v NaCl buffer andmetabolites were extracted three times with cold methanol (80%) and analyzed
by GCMS. For glucose and palmitate tracing into CL, T cells were cultured in IL-2 or IL-15 condition in presence of 11 mM D-[U13C]
glucose or 20 mM [U13C]-Palmitate for 72 h. Medium was changed daily. Cell pellets for lipid extraction were collected at indicated
time points.
Lipid Extraction and Quantification
Lipidswere extracted using a biphasicMethyl tert-butyl ether (MTBE) extraction protocol (adapted fromMatyash et al., 2008). In brief,
cells were resuspended in 100uL cold PBS in glass vials. Cold methanol (750uL), MTBE (2mL), and water (625uL) were added
sequentially with vortexing. Samples were centrifuged to separate phases, and the upper organic phase was dried using a Genevac
EZ2 speed vac. Samples were resuspended in 2:1:1 isopropanol:acetonitrile:water prior to analysis. LC-MSwas carried out using an
Agilent Zorbax Eclipse Plus C18 column using an Agilent 1290 Infinity II UHPLC in line with an Agilent 6495 Triple Quad QQQ-MS.
Lipids were identified by fragmentation and retention time, and were quantified using Agilent Mass Hunter software.
Glucose and Linoleic Acid Tracing into Cardiolipin
Label tracing by LC-MS was carried out using an Agilent 1290 Infinity II UHPLC inline with a Bruker Impact II QTOF-MS operating in
negative ion mode. Scan range was from 50 to 1600 Da. Mass calibration was performed at the beginning of each run. LC separation
was on a Zorbax Eclipse plus C18 column (1003 2mm, 1.8 mmparticles) using a solvent gradient of 70%buffer A (10mMammonium
formiate in 60:40 acetonitrile:water) to 97%buffer B (10mMammonium formiate in 90:10 2-propanol:acetonitrile). Flow rate was from
400 mL/min, autosampler temperature was 5C and injection volume was 2 mL. Data processing including correction for natural
isotope abundance was carried out by an in-house R script.e5 Cell Metabolism 32, 981–995.e1–e7, December 1, 2020
ll
OPEN ACCESSArticleGlucose Tracing into Central Carbon Metabolites
Driedmetabolite extracts were resuspended in pyridine and derivatized with methoxyamine (sc-263468 Santa Cruz Bio) for 60min at
37C and subsequently with N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamid, with 1% tert-utyldimethylchlorosilane (375934
Sigma-Aldrich) for 30min at 80C. Isotopomer distributions weremeasured using aDB5-MSGCcolumn in a 7890GC system (Agilent
Technologies) combined with a 5977 MS system (Agilent Technologies). Data processing, including correction for natural isotope
abundance was performed by an in-house R script.
RT-PCR
RNA isolations were done by using the RNeasy kit (QIAGEN) and single-strand cDNAwas synthesized using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). All RT-PCRwere performed using iTaq Universa Probes Supermix (Biorad) and Taq-
man primers (Thermo Fisher Sceintific) using an Applied Biosystems 7000 sequence detection system. The expression levels of
mRNA were normalized to the expression of a housekeeping gene (HPRT ot ActB).
mtDNA/nDNA Quantification
Genomic DNA was extracted with QIAGEN QIAamp DNA Micro Kit. DNA was quantified, diluted to 10ng/ml and 50 mg of DNA was
used for qPCR analysis of mtDNA (ND1) and nuclear DNA transcripts (Hprt).
Calcium Flux
CD8+ T cells were isolated using CD8+ T cell kit (Stem Cell technologies, Cat# 19853). 3*10^6 cells were loaded 30min at 37C in
humidified incubator with 2uM Indo-AM dissolved in complete medium + 0,5 mM CsH. Then, cells were washed and resuspended
in 300 mL of complete medium supplemented with 0,5 mM CsH and 5 mg/mL anti-mouse CD3 (inVivoMAb Cat# BE0002) 30min at
4C in the dark. At cytofluorimeter indoviolet and indoblue were acquired in linear scale. Tube was placed in 37C temperature-
controlled tube holder immediately before acquisition and signal was acquired as follows: 30 s basal, 6min after addition of Anti-
Rat IgG (Fc-specific)biotin crosslinking antibody (Sigma, SAB3700543, diluted 1:50 directly in the acquisition tube), 2 min after add-
ing tapsigargin (final concentration 100nM) tomeasure endoplasmic reticulum calcium stores depletion, 1min after adding Ionomycin
(final concentration 500 ng/mL) to evaluate maximal calcium flux.
Cell Cycle Analysis
At indicated time points after activation CD8+ T cells were stained with NearIR Live dead staining (Thermofisher) 10min RT in the dark,
fixed in fixative buffer from eBioscience Foxp3 / Transcription Factor Staining Buffer Set (00-5523-00) for 60min at RT. After a wash in
perm buffer, cells were stained with PE-Cy7 Anti-Ki67 antibody in perm buffer 45min 4C in the dark. After additional wash cells were
resuspended in FxCycle (Thermofisher R37166) diluted 1:4000 in PBS immediately before flow cytometry acquisition.
Western Blotting
For western blot analysis, cells were washed with ice cold PBS and lysed in 1 x Cell Signaling lysis buffer (20 mM Tris-HCL [pH
7.5], 150 mM NaCl, 1 mM Na2EDTA, 1mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
1mM Na3VO4, 1 mg/mL leupeptin), supplemented with 1mM PMSF for 30min followed by centrifugation at 20.000 x g for 10 min
at 4C. Cleared protein lysate were quantified using Pierce BCA protein assay kit (Cat#23225) according to manufacturer’s in-
struction. Cleared protein extracts were denatured with LDS loading buffer for 10 min at 70C and loaded onto precast 4% to
12% bis-tris protein gels. Proteins were transferred onto nitrocellulose membranes using the iBLOT2 system following the man-
ufacturers protocols. Membranes were blocked with 5% w/v milk and 0.1% Tween-20 in TBS and incubated with the appro-
priate antibodies in 5% w/v BSA in TBS with 0.1% Tween-20 overnight at 4C. All primary antibody incubations were followed
by incubation with secondary HRP-conjugated antibody (Pierce) in 5% milk and 0.1% Tween-20 in TBS and visualized using
SuperSignal West Pico or Femto Chemiluminescent Substrate (Pierce) on Biomax MR Film (Kodak). Optical density of the sig-
nals on the film was quantified using grayscale measurements in ImageJ software (NIH) and converted to fold change, normal-
ized to the loading control.
Generation of CRISPR KO T Cells
CD8+ T cells were electroporated using Amaxa electroporation systemwith 60 nmol of sgRNA-CAS9 (Alt-R S.p. Cas9 Nuclease V3)
complexes (sgRNAs: Mm.Cas9.TAZ.1AA, Mm.Cas9.TAZ.1AB, Mm.Cas9.TAZ.1C targeting TAZ, Mm.Cas9.PTPMT1.1.AA,
Mm.Cas9.PTPMT1.1.AB, Mm.Cas9.PTPMT1.1.AC targeting PTPMT1) following manufacturer’s guidelines. Naive CD8+ T cells
were cultured for 24 h in IL-7 before being activated with aCD3/aCD28 + IL-2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Flow cytometry data were analyzed using FlowJo 10 (BD Biosciences). Statistical Analyses were performed using Prism 7 software
(GraphPad) and results are represented as Mean ± SEM, unless otherwise indicated. Comparisons for two groups were
calculated using unpaired two-tailed Student’s t tests. Comparisons of more than two groups were calculated using one-way
ANOVA with Tukey multiple comparison tests. We observed normal distribution and no difference in variance between groups inCell Metabolism 32, 981–995.e1–e7, December 1, 2020 e6
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in vivo experiments was based on previous experience with infection experiments. The number of independent experiments per-
formed, and the p values for each experiment are reported in the corresponding figure legends. For both in vitro and in vivo exper-
iments, no initial exclusion criteria were used and no animals or replicates were excluded from the study.e7 Cell Metabolism 32, 981–995.e1–e7, December 1, 2020
